Biopharmaceuticals from Plan to Production - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Biopharmaceuticals from Plan to Production
Management of the product plan and details for biopharmaceutical production are included in an integrated review of biotechnology operations.


Pharmaceutical Technology
Volume 35, Issue 10

The chapter titled “Biomanufacture” does not provide extensive details about how the manufacturing process evolves from the development process. Although the part of the book dedicated to biomanufacturing is complete, each individual production method could have been expanded into its own book, had it covered topics, such as production methods, process development, and integration into manufacturing and technology transfer, in much more depth.

A thorough discussion titled “Biomanufacturing Process for Biotechnology Products” examines recombinant-protein expression, various cell-expression systems (including host cell selection issues), master and working cell banks, and recovery and purification methods. Further discussion of plasmid DNA, live-organism (e.g., bacterial or viral) processes, somatic cells, pluripotent (i.e., stem) cells, transgenic plant and animal sources, and bioactive peptides could each have entire books devoted to their current state of the art and production process. The brief attention given to final-product formulation, fill-finish, labeling and facilities, utilities, and equipment and validation shows how difficult is it to incorporate all of the needs of biopharmaceutical production into one book.

The chapter on quality control outlines the selection of analytical procedures needed to define quality attributes, including specification development, an array of methods for biological product testing, cell banking, stability, raw-material operations, quality in the manufacturing environment, and assay qualification and validation. This section is quite comprehensive, but might have benefited from an expanded discussion on bioassays and their validation.

The last chapters of the book explain the preclinical and clinical components of pharmaceutical and biopharmaceutical development. Discussion of preclinical and nonclinical studies includes all of the needed information on delivery, pharmacology and toxicology, and in vitro safety needs. It also includes an outline of the integration of nonclinical studies with a biopharmaceutical development program. This chapter leads into a chapter on clinical studies that include components of clinical trials from Phase I through Phase IV and notes the special needs of biopharmaceuticals in clinical settings.

The discussion of clinical trials for biopharmaceuticals is appropriately based on clinical trials for small-molecule and nonbiological products and includes details of potential biological interactions that may evolve during early and advanced clinical trials.

Overall, the book emphasizes the components needed in traditional pharmaceutical development and describes the significant differences in the requirements for biopharmaceutical development and operations. A more thorough discussion of the integration of development processes into a defined, validated manufacturing process for biotechnology products would have been a welcome addition.

Many recent books have been written to address the production of pharmaceutical proteins, and most have had problems in portraying the entire topic without missing a component or digressing into tangents. This book presents a complete review of biotechnology operations and would be an exceptionally useful overview for the experienced—and quite instructional for the uninitiated.

Jim Fernandez is president of Fernandez and Associates, 1480 Moraga Rd. #280, Moraga, CA 94556,


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here